Sanara MedTech (SMTI)
NASDAQ:SMTI
SMTI Stock Chart & Stats
$29.52
$0.13(0.40%)
At close: 4:00 PM EST
$29.52
$0.13(0.40%)
Day’s Range― - ―
52-Week Range$16.05 - $35.95
Previous CloseN/A
Volume5.72K
Average Volume (3M)61.65K
Market Cap
$157.49M
Enterprise Value$189.75M
Total Cash (Recent Filing)$16.58M
Total Debt (Recent Filing)$48.19M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 18, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding9,167,040
10 Day Avg. Volume48,775
30 Day Avg. Volume61,645
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)33.96
Price to Sales (P/S)1.95
P/FCF Ratio93.17
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue1.84
Enterprise Value/Gross Profit2.04
Enterprise Value/Ebitda16.07
Forecast
1Y Price Target
$36.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.65
Revenue Forecast (FY)$118.60M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And PartnershipsExpansion of the sales and distribution network and the strategic alliance with Biomimetic Innovations extend commercial reach and increase the chances of faster adoption for new products in hospital channels.
OsStic Clinical DifferentiationOsStic's Breakthrough Device designation combined with preclinical data showing substantially stronger bonding than traditional bone cement indicates meaningful clinical differentiation and potential to displace existing surgical adhesives.
Vizient ContractContract with Vizient secures pre-negotiated terms and contracted pricing for BIASURGE across affiliated hospitals, supporting broader market access and easier procurement by healthcare providers.
Bears Say
Balance Sheet LeverageReported cash balances that are smaller than long-term debt create leverage on the balance sheet and could constrain financial flexibility for operations and strategic initiatives.
Liquidity And Funding RiskA modest cash position alongside significant long-term debt raises the risk of needing dilutive financing or higher-cost borrowing to fund growth, which could pressure shareholder returns.
Sanara MedTech News
SMTI FAQ
What was Sanara MedTech’s price range in the past 12 months?
Sanara MedTech lowest stock price was $16.05 and its highest was $35.95 in the past 12 months.
What is Sanara MedTech’s market cap?
Sanara MedTech’s market cap is $157.49M.
When is Sanara MedTech’s upcoming earnings report date?
Sanara MedTech’s upcoming earnings report date is May 18, 2026 which is in 46 days.
How were Sanara MedTech’s earnings last quarter?
Sanara MedTech released its earnings results on Mar 24, 2026. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of $0.11 by -$0.24.
Is Sanara MedTech overvalued?
According to Wall Street analysts Sanara MedTech’s price is currently Undervalued.
Does Sanara MedTech pay dividends?
Sanara MedTech does not currently pay dividends.
What is Sanara MedTech’s EPS estimate?
Sanara MedTech’s EPS estimate is 0.13.
How many shares outstanding does Sanara MedTech have?
Sanara MedTech has 9,167,040 shares outstanding.
What happened to Sanara MedTech’s price movement after its last earnings report?
Sanara MedTech reported an EPS of -$0.13 in its last earnings report, missing expectations of $0.11. Following the earnings report the stock price went down -1.418%.
Which hedge fund is a major shareholder of Sanara MedTech?
Currently, no hedge funds are holding shares in SMTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanara MedTech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.00 (21.95% Upside)
$36.00 (21.95% Upside)
Blogger Sentiment
Bullish
SMTI Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.65%
12-Months-Change
Fundamentals
Return on Equity
-178.57%
Trailing 12-Months
Asset Growth
-17.20%
Trailing 12-Months
Company Description
Sanara MedTech
Sanara MedTech Inc. (SMTI) is a medical technology company focused on developing and commercializing advanced wound care and regenerative medicine products. The company operates primarily in the healthcare sector, offering innovative solutions designed to improve patient outcomes and promote healing in chronic and acute wounds. Sanara's core product portfolio includes advanced wound dressings and bioactive solutions that utilize its proprietary technologies to facilitate tissue regeneration and healing processes.
SMTI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum and meaningful financial improvement in 2025 — including record revenue, expanded gross margins, materially higher adjusted EBITDA, a positive operating cash flow turnaround, distributor and facility expansion, Vizient contract win, and clear R&D/IP progress. Near-term headwinds include a Q4 continuing-operations net loss, a noncash impairment charge, higher operating expenses driven by strategic investments, a sizable increase in long-term debt, and THP wind-down cash impacts. Management reiterated confident, externally provided guidance for 2026 and plans targeted investments (sales coverage expansion, R&D) to support growth. Overall, the positive operational and financial achievements, plus tangible growth catalysts, outweigh the listed challenges.View all SMTI earnings summariesSMTI Stock 12 Month Forecast
Average Price Target
$36.00
▲(21.95% Upside)
Technical Analysis
InfuSystem Holdings
―
Orasure Technologies
―
Stereotaxis
―
Utah Medical Products
―
Sharps Technology, Inc.
―
Ownership Overview
2.80% Insiders
2.95% Mutual Funds
1.63% Other Institutional Investors
89.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---